Table 5.
Base case analyses stable population
| Strategy | Mean cost (£) | Mean QALY | ICER (£/QALY) | Probability cost-effective* |
| Base case stable population, all studies, pooled mean rate ratio | ||||
| Domiciliary NIV | £25 461 | 4.177 | £27 380 | 4% |
| Usual care | £16 973 | 3.867 | ||
| Incremental difference | £8488 | 0.310 | ||
| Stable population, ‘Western’ settings†, pooled mean rate ratio | ||||
| Domiciliary NIV | £25 373 | 4.007 | £60 000 | 25% |
| Usual care | £16 973 | 3.867 | ||
| Incremental difference | £8400 | 0.14 | ||
*Cost-effective at £20 000/QALY.
†Western studies included studies reporting hospitalisations from Italy, Poland, the Netherlands, Germany and the UK.
ICER, incremental cost-effectiveness ratio; NIV, non-invasive ventilation; QALY, quality-adjusted life year.